×

OncoMed to Present Preclinical Data for the Combination of anti-DLL4/VEGF Bispecific plus anti-PD1 at the Society of Immunotherapy for Cancer Meeting

REDWOOD CITY, Calif., Nov. 04, 2015 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) announced that new data comparing the anti-tumor immune response of its anti-DLL4/VEGF bispecific alone and in combination with anti-Programmed Cell Death Protein 1 (PD1) will be presented at the upcoming Society of Immunotherapy for Cancer (SITC) 30th Annual Meeting taking place November 4-8, 2015 in National Harbor, MD.

Saturday, November 7, 2015 - 12:45 pm – 2:00 pm

Title: Co-Targeting of Delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF) with Programmed Death 1 (PD1) blockade inhibits tumor growth and facilitates anti-tumor immune responses

Lead author: Angie Park, PhD, Director of Immunotherapy and Stem Cell Biology, of OncoMed

Session: Optimizing Combination Immunotherapy

About OncoMed Pharmaceuticals

OncoMed Pharmaceuticals is a clinical-stage company focused on discovering and developing novel anti-cancer stem cell and immuno-oncology therapeutics. OncoMed has seven anti-cancer product candidates in clinical development, including demcizumab (anti-DLL4, OMP-21M18), tarextumab (anti-Notch2/3, OMP-59R5), brontictuzumab (anti-Notch1, OMP-52M51), anti-DLL4/VEGF bispecific antibody (OMP-305B83), vantictumab (anti-FZD7, OMP-18R5), ipafricept (FZD8-Fc, OMP-54F28), and anti-RSPO3 (OMP-131R10), which each target key cancer stem cell signaling pathways including Notch, Wnt and R-spondin-LGR. OncoMed is also pursuing discovery of additional novel anti-CSC and cancer immunotherapy product candidates. OncoMed has formed strategic alliances with Celgene Corporation, Bayer Pharma AG and GlaxoSmithKline (GSK). Additional information can be found at the company's website: www.oncomed.com.

Contact:
OncoMed Pharmaceuticals
Michelle Corral
Senior Director, Investor Relations and Corporate Communications
michelle.corral@oncomed.com
(650) 995-8373

Investors
Shari Annes
Annes Associates
shari.annes@oncomed.com
(650) 888-0902


Source:OncoMed Pharmaceuticals, Inc.